Phase II Trial of the Antiangiogenic Agent Thalidomide in Patients With Recurrent High-Grade Gliomas

Tumor Angiogenesis: Therapeutic Implications

1971 • 9,898 citations

Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis

1996 • 6,878 citations

Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis

1992 • 4,631 citations

Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth

1997 • 4,504 citations

Thalidomide is an inhibitor of angiogenesis.

1994 • 2,460 citations

Response criteria for phase II studies of supratentorial malignant glioma.

1990 • 2,401 citations

Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo

1992 • 2,293 citations

Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth

1990 • 1,308 citations

Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant

1994 • 1,249 citations

Primary central nervous system lymphoma

1988 • 811 citations

The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth

1994 • 743 citations

Combined modality therapy for primary CNS lymphoma.

1992 • 543 citations

Effects of Thalidomide and Related Metabolites in a Mouse Corneal Model of Neovascularization

1997 • 447 citations

Thalidomide in the Treatment of the Mucocutaneous Lesions of the Behcet Syndrome

1998 • 445 citations

Thalidomide for the Treatment of Oral Aphthous Ulcers in Patients with Human Immunodeficiency Virus Infection

1997 • 423 citations

Tumor Angiogenesis: A Quantitative Method for Histologic Grading<xref ref-type="fn" rid="FN2">2</xref>

1972 • 418 citations

Primary Central Nervous System Lymphoma

1993 • 394 citations

Tumor angiogenesis in breast cancer: Its importance as a prognostic indicator and the association with vascular endothelial growth factor expression

1995 • 376 citations

Successful chemotherapy for recurrent malignant oligodendroglioma

1988 • 346 citations

Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease.

1992 • 259 citations

Potentiation of cytotoxic cancer therapies by TNP‐470 alone and with other anti‐angiogenic agents

1994 • 241 citations

Inhibition of IL-12 production by thalidomide.

1997 • 204 citations

Criteria for evaluating patients undergoing chemotherapy for malignant brain tumors

1977 • 201 citations

Coexpression of platelet-derived growth factor (PDGF) and PDGF-receptor genes by primary human astrocytomas may contribute to their development and maintenance.

1990 • 177 citations

Viral vector-targeted antiangiogenic gene therapy utilizing an angiostatin complementary DNA.

1998 • 173 citations

Immunohistochemical localization of basic fibroblast growth factor in astrocytomas.

1990 • 167 citations

Correlation of basic fibroblast growth factor expression levels with the degree of malignancy and vascularity in human gliomas

1992 • 166 citations

Inhibition of angiogenesis and tumor growth by a synthetic laminin peptide, CDPGYIGSR-NH2.

1991 • 157 citations

Inhibition of angiogenesis in human glioblastomas by chromosome 10 induction of thrombospondin-1.

1996 • 145 citations

The basis for current treatment recommendations for malignant gliomas

1994 • 135 citations

The role of thalidomide in the treatment of refractory chronic graft-versus-host disease following bone marrow transplantation in children

1998 • 82 citations

Comparison of several antiangiogenic regimens alone and with cytotoxic therapies in the Lewis lung carcinoma

1996 • 75 citations

Inhibition of growth and angiogenesis of human neurofibrosarcoma by heparin and hydrocortisone

1990 • 40 citations